Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Damora Therapeutics, Inc. (DMRA) · filed Apr 7, 2023

Accession no.
0000947871-23-000438
Filed
Apr 7, 2023, 4:42 PM ET
Trade date
Apr 5-6, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions. Open-market sales total $222.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 000105595110% Owner
OrbiMed Israel GP II, L.P.CIK 000168209010% Owner
OrbiMed Advisors Israel II LtdCIK 000168209310% Owner
OrbiMed Capital GP VII LLCCIK 000176064810% Owner
OrbiMed Genesis GP LLCCIK 000180874410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 5, 2023Common StockSSaleDisposed−4,687$2.18−$10,217.66187,100Indirect
Apr 5, 2023Common StockSSaleDisposed−25,220$2.18−$54,979.61,006,591Indirect
Apr 5, 2023Common StockSSaleDisposed−63,058$2.18−$137,466.442,516,599Indirect
Apr 6, 2023Common StockSSaleDisposed−487$2.00−$974186,613Indirect
Apr 6, 2023Common StockSSaleDisposed−2,620$2.00−$5,2401,003,971Indirect
Apr 6, 2023Common StockSSaleDisposed−6,558$2.00−$13,1162,510,041Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)